Suppr超能文献

与传统型癌肉瘤相比,存在 DNA 错配修复缺陷的子宫内膜癌肉瘤具有明显不同的临床、形态学和分子特征。

DNA Mismatch Repair-deficient Endometrial Carcinosarcomas Portend Distinct Clinical, Morphologic, and Molecular Features Compared With Traditional Carcinosarcomas.

机构信息

Department of Pathology.

Morristown Medical Center, Morristown, NJ.

出版信息

Am J Surg Pathol. 2020 Nov;44(11):1573-1579. doi: 10.1097/PAS.0000000000001561.

Abstract

Uterine carcinosarcomas (UCSs) are aggressive neoplasms composed of high-grade malignant epithelial and mesenchymal elements with most (∼90%) showing TP53 abnormalities. A subset, however, shows mismatch repair deficiency (MMR-D). We sought to describe their clinical, morphologic, and molecular features. Clinicopathologic data of MMR-D UCSs were recorded including age, stage, follow-up, mismatch repair and p53 immunohistochemistry (IHC), MLH1 promoter methylation status, and germline alterations, TP53 mutation status, microsatellite instability and mutational burden by massively parallel sequencing. Seventeen (6.2%) MMR-D were identified among 276 UCSs. Of MMR-D UCSs, the median age was 60 years. mismatch repair IHC loss is as follows: MLH1/PMS2 65%, MSH2/MSH6 18%, MSH6 12%, and PMS2 6%. MLH1 promoter methylation and Lynch syndrome was identified in 47% and 12% of cases, respectively. Cases with p53 IHC showed the following patterns: wild-type 70%, aberrant 20%, and equivocal 10%. Of cases with sequencing, 88% were hypermutated and microsatellite instability high. High-grade endometrioid, undifferentiated, and clear cell carcinoma was present in 53%, 41%, and 6% of cases, respectively and 47% also showed a low-grade endometrioid component. Most patients presented at an early stage (67%) and upon follow-up, 18% died of disease, 65% showed no evidence of disease, while 18% are alive with disease. Patients with MMR-D UCS are younger than the reported median age (70 y) for traditional UCS and most do not show p53 abnormalities. Low-grade endometrioid and undifferentiated carcinoma were seen in approximately half of all cases. Although UCSs have a high tendency for early extrauterine spread, most patients in our cohort presented at an early stage and at follow-up were no evidence of disease. MMR-D UCSs display distinct clinical, morphologic, and molecular features compared with traditional UCSs.

摘要

子宫癌肉瘤(UCS)是由高级别恶性上皮和间叶成分组成的侵袭性肿瘤,大多数(约 90%)存在 TP53 异常。然而,有一部分表现为错配修复缺陷(MMR-D)。我们旨在描述其临床、形态学和分子特征。记录了 MMR-D UCS 的临床病理数据,包括年龄、分期、随访、错配修复和 p53 免疫组化(IHC)、MLH1 启动子甲基化状态、种系改变、TP53 突变状态、微卫星不稳定性和突变负担的大规模平行测序。在 276 例 UCS 中发现了 17 例(6.2%)MMR-D。在 MMR-D UCS 中,中位年龄为 60 岁。MMR 免疫组化缺失如下:MLH1/PMS2 65%,MSH2/MSH6 18%,MSH6 12%,PMS2 6%。分别在 47%和 12%的病例中发现 MLH1 启动子甲基化和林奇综合征。有 p53 IHC 的病例表现为以下模式:野生型 70%,异常 20%,可疑 10%。在有测序的病例中,88%为高突变和微卫星不稳定高。高级别子宫内膜样癌、未分化癌和透明细胞癌分别占 53%、41%和 6%,47%还表现为低级别子宫内膜样癌成分。大多数患者在早期阶段(67%)就诊,随访时,18%死于疾病,65%无疾病证据,18%仍有疾病。与传统 UCS 报道的中位年龄(70 岁)相比,MMR-D UCS 的患者年龄更年轻,大多数患者没有 p53 异常。大约一半的病例中可见低级别子宫内膜样癌和未分化癌。尽管 UCS 有早期子宫外扩散的高倾向,但我们队列中的大多数患者在早期就诊,随访时无疾病证据。与传统 UCS 相比,MMR-D UCS 具有明显的临床、形态学和分子特征。

相似文献

4
[Comprehensive assessment of mismatch repair and microsatellite instability status in molecular classification of endometrial carcinoma].
Zhonghua Fu Chan Ke Za Zhi. 2023 Oct 25;58(10):755-765. doi: 10.3760/cma.j.cn112141-20230711-00316.
5
Mismatch Repair Deficiency in Uterine Carcinosarcoma: A Multi-institution Retrospective Review.
Am J Surg Pathol. 2020 Jun;44(6):782-792. doi: 10.1097/PAS.0000000000001434.
7
Lessons learnt from implementation of a Lynch syndrome screening program for patients with gynaecological malignancy.
Pathology. 2017 Aug;49(5):457-464. doi: 10.1016/j.pathol.2017.05.004. Epub 2017 Jun 30.
8
Analysis of 108 patients with endometrial carcinoma using the PROMISE classification and additional genetic analyses for MMR-D.
Gynecol Oncol. 2020 Apr;157(1):245-251. doi: 10.1016/j.ygyno.2020.01.019. Epub 2020 Jan 21.

引用本文的文献

1
TROP2 expression and therapeutic targeting in uterine carcinosarcoma.
Gynecol Oncol. 2025 Jun;197:129-138. doi: 10.1016/j.ygyno.2025.04.590. Epub 2025 May 8.
2
Meta-analysis of the clinicopathologic features of endometrial cancer molecular staging.
Front Oncol. 2025 Jan 7;14:1510102. doi: 10.3389/fonc.2024.1510102. eCollection 2024.
5
Exploring biomarkers and prognostic factors in uterine carcinosarcoma: An insight into L1CAM, CDX2, p53, and MSI status.
PLoS One. 2023 May 18;18(5):e0285447. doi: 10.1371/journal.pone.0285447. eCollection 2023.
6
Germline drivers of gynecologic carcinosarcomas.
Gynecol Oncol. 2023 Jul;174:34-41. doi: 10.1016/j.ygyno.2023.04.024. Epub 2023 May 5.
7
Dedifferentiated endometrial carcinoma arising from serous carcinoma: Diagnostic challenges and recommendations.
Gynecol Oncol Rep. 2023 Apr 13;47:101188. doi: 10.1016/j.gore.2023.101188. eCollection 2023 Jun.
10
Management and Prognosis of Patients with Recurrent or Persistent/Progressive Uterine Carcinosarcoma.
Curr Oncol. 2022 Oct 13;29(10):7607-7623. doi: 10.3390/curroncol29100601.

本文引用的文献

1
Mismatch Repair Deficiency in Uterine Carcinosarcoma: A Multi-institution Retrospective Review.
Am J Surg Pathol. 2020 Jun;44(6):782-792. doi: 10.1097/PAS.0000000000001434.
2
Clinicopathological and molecular characterisation of 'multiple-classifier' endometrial carcinomas.
J Pathol. 2020 Mar;250(3):312-322. doi: 10.1002/path.5373. Epub 2020 Jan 12.
3
p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies.
J Pathol. 2020 Mar;250(3):336-345. doi: 10.1002/path.5375. Epub 2020 Jan 29.
4
High-Grade Endometrial Carcinomas: Classification with Molecular Insights.
Surg Pathol Clin. 2019 Jun;12(2):343-362. doi: 10.1016/j.path.2019.02.003.
5
Predictive Histologic Factors in Carcinosarcomas of the Uterus: A Multi-institutional Study.
Int J Gynecol Pathol. 2019 May;38(3):205-215. doi: 10.1097/PGP.0000000000000497.
6
High-grade Endometrial Carcinomas: Morphologic and Immunohistochemical Features, Diagnostic Challenges and Recommendations.
Int J Gynecol Pathol. 2019 Jan;38 Suppl 1(Iss 1 Suppl 1):S40-S63. doi: 10.1097/PGP.0000000000000491.
8
Prognostic factors impacting survival in early stage uterine carcinosarcoma.
Gynecol Oncol. 2019 Jan;152(1):31-37. doi: 10.1016/j.ygyno.2018.10.034. Epub 2018 Nov 8.
9
10
Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups.
Am J Surg Pathol. 2018 May;42(5):561-568. doi: 10.1097/PAS.0000000000001020.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验